Ocular Therapeutix (OCUL) Invested Capital (2013 - 2026)

Ocular Therapeutix's Invested Capital history runs 14 years deep, the most recent figure standing at $581.6 million for Q1 2026.

• In Q1 2026, Invested Capital rose 118.69% year-over-year to $581.6 million; the TTM figure through Mar 2026 stood at $581.6 million (up 118.69% YoY), while the FY2025 annual figure was $654.3 million, up 107.49% from the prior year.
• Invested Capital was $581.6 million for Q1 2026 at Ocular Therapeutix, down from $654.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $654.3 million in Q4 2025 to a low of $3.1 million in Q2 2023.
• Historically, Invested Capital has averaged $234.3 million across 5 years, with a median of $258.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Invested Capital plunged 95.31% in 2023, then surged 12135.02% in 2024.
• A 5-year view of Invested Capital shows it stood at $72.9 million in 2022, then soared by 76.49% to $128.6 million in 2023, then jumped by 145.15% to $315.3 million in 2024, then surged by 107.49% to $654.3 million in 2025, then fell by 11.12% to $581.6 million in 2026.
• The last three Invested Capital figures came in at $581.6 million (Q1 2026), $654.3 million (Q4 2025), and $258.2 million (Q3 2025), per Business Quant data.